IN2014DN01619A - - Google Patents

Info

Publication number
IN2014DN01619A
IN2014DN01619A IN1619DEN2014A IN2014DN01619A IN 2014DN01619 A IN2014DN01619 A IN 2014DN01619A IN 1619DEN2014 A IN1619DEN2014 A IN 1619DEN2014A IN 2014DN01619 A IN2014DN01619 A IN 2014DN01619A
Authority
IN
India
Prior art keywords
relates
present
bisbenzonitrile
triazol
medicaments
Prior art date
Application number
Other languages
English (en)
Inventor
Ann Taylor
Lloyd B Klickstein
Jeewan Thakur
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN01619(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN01619A publication Critical patent/IN2014DN01619A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1619DEN2014 2011-09-08 2012-09-06 IN2014DN01619A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532459P 2011-09-08 2011-09-08
US201261638588P 2012-04-26 2012-04-26
PCT/US2012/053846 WO2013036563A1 (en) 2011-09-08 2012-09-06 Pharmaceutical compositions comprising an aromatase inhibitor

Publications (1)

Publication Number Publication Date
IN2014DN01619A true IN2014DN01619A (zh) 2015-05-15

Family

ID=46846026

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1619DEN2014 IN2014DN01619A (zh) 2011-09-08 2012-09-06

Country Status (30)

Country Link
US (4) US9370505B2 (zh)
EP (2) EP2753313B1 (zh)
JP (2) JP6280501B2 (zh)
KR (3) KR20180030254A (zh)
CN (2) CN103781476B (zh)
AR (1) AR087790A1 (zh)
AU (2) AU2012304694B2 (zh)
BR (2) BR112014004879B1 (zh)
CA (2) CA2845929C (zh)
CL (1) CL2014000552A1 (zh)
CY (2) CY1118461T1 (zh)
DK (2) DK2753313T3 (zh)
ES (2) ES2613667T3 (zh)
HR (2) HRP20170002T1 (zh)
HU (2) HUE031435T2 (zh)
IL (1) IL231234A (zh)
IN (1) IN2014DN01619A (zh)
LT (2) LT2753313T (zh)
MX (2) MX343902B (zh)
PE (1) PE20141584A1 (zh)
PL (2) PL2753313T3 (zh)
PT (2) PT2753313T (zh)
RU (2) RU2617510C2 (zh)
SG (2) SG2014012132A (zh)
SI (2) SI2753313T1 (zh)
TN (1) TN2014000059A1 (zh)
TW (1) TW201316987A (zh)
UY (1) UY34315A (zh)
WO (2) WO2013036563A1 (zh)
ZA (1) ZA201401040B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2613667T3 (es) * 2011-09-08 2017-05-25 Mereo Biopharma 2 Limited Composiciones farmacéuticas que comprenden un inhibidor de aromatasa
WO2015148549A1 (en) * 2014-03-26 2015-10-01 The Regents Of The University Of California Ultrasensitive androgen receptor bioassay
JP6731136B2 (ja) * 2014-07-07 2020-07-29 レコルダティ アーゲー 医薬製剤
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
EP3592338A1 (en) * 2017-03-08 2020-01-15 ARIAD Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4
USD894148S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
USD894149S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
JP7121999B2 (ja) * 2019-09-26 2022-08-19 学校法人九州文化学園 男性性腺機能低下症治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
TW210334B (zh) * 1990-12-12 1993-08-01 Ciba Geigy Ag
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
WO2002002113A1 (en) * 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
AU2002249041B2 (en) 2001-04-17 2007-07-12 Ares Trading S.A. Aromatase inhibition to enhance assisted reproduction
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US20040235812A1 (en) 2002-04-03 2004-11-25 Caspers Robert F Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
CA2605796A1 (en) 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CN102335269B (zh) 2007-11-21 2013-06-19 客乐谐制药株式会社 芳香酶抑制剂
ES2613667T3 (es) * 2011-09-08 2017-05-25 Mereo Biopharma 2 Limited Composiciones farmacéuticas que comprenden un inhibidor de aromatasa

Also Published As

Publication number Publication date
PT2753313T (pt) 2017-02-02
RU2014113334A (ru) 2015-10-20
PL2753312T3 (pl) 2017-06-30
ES2613667T3 (es) 2017-05-25
CY1118461T1 (el) 2017-07-12
CL2014000552A1 (es) 2014-09-12
NZ621476A (en) 2016-02-26
US9295668B2 (en) 2016-03-29
LT2753312T (lt) 2017-01-25
DK2753312T3 (da) 2017-02-13
HRP20170002T1 (hr) 2017-02-24
BR112014004879A2 (pt) 2017-03-14
SI2753312T1 (sl) 2017-10-30
BR112014005434B1 (pt) 2021-01-05
PE20141584A1 (es) 2014-11-13
US9750724B2 (en) 2017-09-05
AU2012304693A1 (en) 2014-03-13
CY1118499T1 (el) 2017-07-12
WO2013036563A1 (en) 2013-03-14
CN103781476A (zh) 2014-05-07
KR101872561B1 (ko) 2018-06-28
US20140213622A1 (en) 2014-07-31
SG2014012132A (en) 2014-06-27
HUE031435T2 (en) 2017-07-28
MX343902B (es) 2016-11-28
MX2014002773A (es) 2014-06-05
JP6051467B2 (ja) 2016-12-27
CN103796644A (zh) 2014-05-14
KR20140058619A (ko) 2014-05-14
TW201316987A (zh) 2013-05-01
DK2753313T3 (en) 2017-02-13
MX2014002780A (es) 2014-06-05
RU2617510C2 (ru) 2017-04-25
WO2013036562A1 (en) 2013-03-14
EP2753313B1 (en) 2016-12-14
PL2753313T3 (pl) 2017-07-31
BR112014004879B1 (pt) 2020-01-28
JP2014526465A (ja) 2014-10-06
US20140309267A1 (en) 2014-10-16
BR112014005434A2 (pt) 2017-04-04
ES2613666T3 (es) 2017-05-25
HUE031478T2 (hu) 2017-07-28
HRP20170003T1 (hr) 2017-03-10
PT2753312T (pt) 2017-02-03
AR087790A1 (es) 2014-04-16
LT2753313T (lt) 2017-02-10
US20160346257A1 (en) 2016-12-01
CN103781476B (zh) 2016-12-07
KR20140071358A (ko) 2014-06-11
MX360315B (es) 2018-10-29
SI2753313T1 (sl) 2017-04-26
KR20180030254A (ko) 2018-03-21
EP2753312B1 (en) 2016-12-14
AU2012304694A1 (en) 2014-03-20
JP6280501B2 (ja) 2018-02-14
SG10201607503WA (en) 2016-10-28
EP2753312A1 (en) 2014-07-16
CA2845929A1 (en) 2013-03-14
US20160243084A1 (en) 2016-08-25
CN103796644B (zh) 2017-05-03
IL231234A0 (en) 2014-04-30
CA2846884A1 (en) 2013-03-14
US9370505B2 (en) 2016-06-21
AU2012304694B2 (en) 2016-04-07
EP2753313A1 (en) 2014-07-16
AU2012304693B2 (en) 2016-03-31
JP2014528932A (ja) 2014-10-30
US10064844B2 (en) 2018-09-04
RU2014113575A (ru) 2015-10-20
RU2628808C2 (ru) 2017-08-22
UY34315A (es) 2013-04-30
CA2846884C (en) 2019-04-09
TN2014000059A1 (en) 2015-07-01
IL231234A (en) 2016-12-29
ZA201401040B (en) 2015-12-23
CA2845929C (en) 2018-06-19

Similar Documents

Publication Publication Date Title
IN2014DN01619A (zh)
TN2015000278A1 (en) Autotaxin inhibitors
IL231226A (en) Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases
MY160456A (en) Benzodiazepine bromodomain inhibitor
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
EP2522653A4 (en) BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
MX2012013703A (es) Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
MX2013001677A (es) Formulaciones estables de linaclotida.
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
MX359288B (es) Forma iv del clorhidrato de ivabradina.
PH12015501096A1 (en) Composition for immediate and extended release
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
MX2015004362A (es) Derivados de ketamina.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX363699B (es) Producto de comicronizacion que comprende acetato de ulipristal.
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
WO2012002773A3 (en) Phenylcarbamate compound and muscle relaxant containing the same
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MX2009007429A (es) Compuestos de piridina y su uso como antagonistas de p2y12.
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
EP2799082A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORAL DISEASES OR ASTHMA CONTAINING A STOREM STEREMIA OVALIFOLIA EXTRACT OR A FRACTION OF IT AS AN ACTIVE SUBSTANCE
WO2012155226A8 (pt) Processo para a produção de derivados de pyrostegia venusta, derivados de pyrostegia venusta, composições farmacêuticas e seus usos